These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 37881221

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.
    Yu B, Zhang N, Feng Y, Zhang Y, Zhang T, Wang L.
    J Hepatocell Carcinoma; 2023; 10():1735-1748. PubMed ID: 37822726
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
    He MK, Le Y, Li QJ, Yu ZS, Li SH, Wei W, Guo RP, Shi M.
    Chin J Cancer; 2017 Oct 23; 36(1):83. PubMed ID: 29061175
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization.
    Lin LW, Ke K, Yan LY, Chen R, Huang JY.
    Front Oncol; 2023 Oct 23; 13():1178428. PubMed ID: 37207144
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience.
    Luo L, Xiao Y, Zhu G, Huang A, Song S, Wang T, Ge X, Xie J, Deng W, Hu Z, Wen W, Mei H, Wan R, Shan R.
    Front Oncol; 2022 Oct 23; 12():1004652. PubMed ID: 36237309
    [Abstract] [Full Text] [Related]

  • 11. Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib.
    Wang J, Zhao M, Han G, Han X, Shi J, Mi L, Li N, Yin X, Duan X, Hou J, Yin F.
    Technol Cancer Res Treat; 2023 Oct 23; 22():15330338231166765. PubMed ID: 37161343
    [Abstract] [Full Text] [Related]

  • 12. Comparative study on the efficacy and safety of transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for large unresectable hepatocellular carcinoma.
    Yang J, Shang X, Li J, Wei N.
    J Gastrointest Oncol; 2024 Feb 29; 15(1):346-355. PubMed ID: 38482220
    [Abstract] [Full Text] [Related]

  • 13. [Study on the comparison of postoperative liver injury caused by hepatic arterial perfusion chemotherapy combined with targeted immunotherapy with hepatic arterial chemoembolization combined with targeted immunotherapy for intermediate-and advanced-stage liver cancer].
    Li R, Li WL, Yuan GS, Pang HJ, Li Q, Hu XY, Guo YB, Chen JZ, Zang MY.
    Zhonghua Gan Zang Bing Za Zhi; 2023 Nov 20; 31(11):1163-1168. PubMed ID: 38238949
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of transarterial therapy combined with first-line tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a network meta-analysis.
    Hu L, Lin J, Shi X, Wang A.
    World J Surg Oncol; 2023 Jul 21; 21(1):208. PubMed ID: 37475030
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and Safety of HepaSphere Drug-Eluting Bead Transarterial Chemoembolization Combined with Hepatic Arterial Infusion Chemotherapy as the Second-Line Treatment in Advanced Hepatocellular Carcinoma.
    Liu B, Gao S, Guo J, Kou F, Liu S, Zhang X, Feng A, Wang X, Cao G, Chen H, Liu P, Xu H, Gao Q, Yang R, Xu L, Zhu X.
    J Hepatocell Carcinoma; 2024 Jul 21; 11():477-488. PubMed ID: 38463543
    [Abstract] [Full Text] [Related]

  • 16. Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy Combined a Tyrosine Kinase Inhibitor for Treatment of Large Hepatocellular Carcinoma.
    Chen B, Dai H, Yang J, Zhang G, Wen C, Xiang X, Lin R, Huang Y.
    Curr Cancer Drug Targets; 2023 Jul 21; 23(7):564-571. PubMed ID: 36790005
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The treatment of transarterial chemoembolization/hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor is effective against hepatocellular carcinoma with portal vein tumor thrombus: A systematic review.
    Yuanren G, Yin L, Liu R, Cui Y.
    Front Oncol; 2023 Jul 21; 13():1054072. PubMed ID: 36969065
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of PD-1 inhibitors plus anti-angiogenesis tyrosine kinase inhibitors with or without transarterial chemo(embolization) for unresectable hepatocellular carcinoma: a meta-analysis.
    Chen Y, Jia L, Li Y, Cui W, Wang J, Zhang C, Bian C, Luo T.
    Front Oncol; 2024 Jul 21; 14():1364345. PubMed ID: 39239275
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.